Zacks Investment Research upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a research note released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $1.00 price objective on the biotechnology company’s stock.
According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “
Several other analysts have also recently commented on NBRV. Northland Securities decreased their target price on Nabriva Therapeutics from $2.50 to $1.50 and set an outperform rating for the company in a research report on Monday, June 22nd. ValuEngine raised Nabriva Therapeutics from a hold rating to a buy rating in a research report on Friday, May 1st. BidaskClub raised Nabriva Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, July 23rd. Finally, HC Wainwright reaffirmed a hold rating on shares of Nabriva Therapeutics in a research report on Friday, August 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Nabriva Therapeutics has an average rating of Hold and a consensus target price of $3.36.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. Nabriva Therapeutics had a negative return on equity of 212.02% and a negative net margin of 932.58%. Analysts forecast that Nabriva Therapeutics will post -0.59 earnings per share for the current year.
Large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of Nabriva Therapeutics in the 2nd quarter valued at $42,000. Exane Derivatives bought a new position in Nabriva Therapeutics during the 1st quarter worth about $47,000. Hudson Bay Capital Management LP bought a new position in Nabriva Therapeutics during the 2nd quarter worth about $54,000. Wells Fargo & Company MN increased its holdings in Nabriva Therapeutics by 28.4% during the 1st quarter. Wells Fargo & Company MN now owns 110,493 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 24,426 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in Nabriva Therapeutics during the 2nd quarter worth about $132,000. 1.60% of the stock is currently owned by hedge funds and other institutional investors.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Article: Most Active Stocks: Dollar Volume vs Share Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.